Short Review of Phase II Study of Erlotinib Plus Gemcitabine in First-Line Treatment of Poor Prognosis, Advanced Non-Small Cell Lung Cancer(NSCLC) Patients- 8 Years Letter

Alexandru Calin Grigorescu

Chemotherapy of patients with advanced NSCLC and poor performance status remain a challenge for clinicians and researchers. After 8 years from the beginning of our study“Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer (NSCLC) patients”, the things are not enough clear regarding the combination of target therapy or immunotherapy for patients with advanced NSCLC. This review tries to discuss some important meth-analysis and some important study which give us more information and solutions to resolve this matter. Conclusion is that some of results of our study remain valuable and more efforts should be done to find the best combination and sequentially between TKI and chemotherapy and between immunotherapy and chemotherapy. In the same spirit we consider and the challenge of studying the combination of targeted therapy and immunotherapy.